RedHill Biopharm announced that the U.S. Patent and Trademark Office, USPTO, had issued a Notice of Allowance for a new opaganib patent covering sphingosine kinase 2 inhibition treatment for Ebola virus disease, supporting opaganib pro tection until October 2035. The Company also announced that the European Patent Office has granted RHB-102 a new patent, covering ondansetron extended-release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms. This new patent is expected to provide protection of RHB-102 across multiple indications until March 2035.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RDHL:
- RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
- RedHill Biopharma files to sell 1.99M American Depositary Shares for holders
- RedHill Biopharma: Talicia approved in the United Arab Emirates
- RedHill Biopharma: RHB-107 included in Government-supported COVID-19 trial
- RedHill Biopharma announces registered direct offering, warrant exercise
Questions or Comments about the article? Write to editor@tipranks.com